|
Aug 5
|
CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption
|
|
Aug 5
|
VRTX Q2 Earnings Beat, Stock Down as Pain Drug Misses Study Goal
|
|
Aug 5
|
Up 50% in 3 Months, Is This Stock Still a Buy?
|
|
Aug 4
|
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates
|
|
Aug 4
|
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
|
|
Aug 2
|
CRISPR Therapeutics (CRSP) Sees 47% Price Increase Over Last Quarter
|
|
Aug 1
|
New Strong Sell Stocks for August 1st
|
|
Jul 30
|
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
|
|
Jul 30
|
Should You Invest in CRISPR Therapeutics (CRSP) Based on Bullish Wall Street Views?
|
|
Jul 29
|
Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know
|
|
Jul 29
|
Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
|
|
Jul 29
|
New Strong Sell Stocks for July 29th
|
|
Jul 29
|
The 3 Things That Matter for CRISPR Therapeutics Now
|
|
Jul 28
|
CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards?
|
|
Jul 28
|
CRISPR Therapeutics AG (CRSP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
|
|
Jul 25
|
CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know
|
|
Jul 24
|
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
|
|
Jul 24
|
[Latest] Global CRISPR Gene Editing Market Size/Share Worth USD 12.6 Billion by 2034 at a 13.01% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
|
|
Jul 23
|
CRISPR Therapeutics (CRSP) Surges 71% Last Quarter With Inclusion In Russell Indices
|
|
Jul 19
|
CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading
|